TABLE 1.
Participant characteristics.
| Non‐Hispanic White (N = 24,216) | Non‐Hispanic Black (N = 3367) | Cross‐ancestry (N = 27,583) | ||||
|---|---|---|---|---|---|---|
| Men | Women | Men | Women | Men | Women | |
| N (total) | 11,062 | 13,154 | 880 | 2487 | 11,942 | 15,641 |
| Baseline characteristics | ||||||
| Age at first cognitive visit (mean years ± SD) | 74.35 ± 7.73 | 74.56 ± 8.13 | 72.79 ± 7.27 | 73.39 ± 7.62 | 74.24 ± 7.71 | 74.37 ± 8.06 |
| Education (mean years ± SD) | 16.36 ± 3.06 | 15.39 ± 2.85 | 14.33 ± 3.43 | 14.41 ± 3.16 | 16.21 ± 3.13 | 15.23 ± 2.92 |
| Memory score (mean score ± SD) | 0.16 ± 0.83 | 0.36 ± 0.90 | 0.04 ± 0.79 | 0.24 ± 0.80 | 0.15 ± 0.82 | 0.34 ± 0.88 |
| Longitudinal characteristics | ||||||
| Number of visits (mean ± SD) | 7.40 ± 4.29 | 8.29 ± 4.67 | 6.93 ± 3.50 | 7.80 ± 4.07 | 7.37 ± 4.25 | 8.22 ± 4.59 |
| Years of follow‐up (mean years ± SD) | 3.84 ± 3.95 | 4.42 ± 4.32 | 3.52 ± 3.38 | 3.98 ± 3.74 | 3.82 ± 3.93 | 4.36 ± 4.24 |
| Memory decline score (mean slope ± SD) | −0.09 ± 0.10 | −0.07 ± 0.10 | −0.08 ± 0.09 | −0.06 ± 0.08 | −0.09 ± 0.10 | −0.07 ± 0.10 |
| Clinical diagnosis at first cognitive visit | ||||||
| N (%) normal cognition (out of those diagnosed) | 4950 (44.75%) | 7839 (59.59%) | 391 (44.43%) | 1384 (55.65%) | 5341 (44.72%) | 9223 (58.97%) |
| N (%) MCI/AD (out of those diagnosed) | 4478 (40.48%) | 3987 (30.31%) | 373 (42.39%) | 869 (34.94%) | 4851 (40.62%) | 4856 (31.05%) |
| APOE carrier status | ||||||
| N (%) ɛ2 carrier (out of those that have APOE data) | 1329 (12.01%) | 1623 (12.34%) | 173 (19.66%) | 457 (18.38%) | 1502 (12.58%) | 2080 (13.30%) |
| N (%) ɛ4 carrier (out of those that have APOE data) | 4154 (39.35%) | 4766 (36.23%) | 415 (47.16%) | 1047 (42.10%) | 4569 (38.26%) | 5813 (37.17%) |
Abbreviation: APOE, apolipoprotein E; MCI/AD, mild cognitive impairment.